AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to bridging the gap between laboratory and patient-centric medicine. Our core technology, the R³CE® platform, is an FDA-approved Class I, scaffold-free, and animal-free system that rapidly expands minimal patient samples into functional 3D organoids within days—enabling personalized oncology and advanced drug discovery.